Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Stanford, California 94305


RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of a chemotherapy drug by making cancer cells more sensitive to the drug. Combining oblimersen with rituximab and combination chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of oblimersen when given together with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in treating patients with stage II, stage III, or stage IV large B-cell lymphoma

Study summary:

OBJECTIVES: Primary - Determine the feasibility and safety of oblimersen administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, in terms of short-term and long-term toxicity, in patients with previously untreated stage III or IV or extensive or bulky stage II diffuse large B-cell lymphoma. - Determine the maximum tolerated dose of oblimersen administered with this regimen in these patients. Secondary - Determine the remission rate and failure-free, progression-free, and overall survival of patients treated with this regimen. OUTLINE: This is a nonrandomized, non-blinded, multicenter, dose-escalation study of oblimersen. Patients receive CHOP-R* therapy comprising cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-10 minutes, vincristine IV, and rituximab IV over 30-90 minutes on day 1 and oral prednisone on days 1-5. Patients also receive oblimersen IV continuously on days -4 to 3. Treatment repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity. Patients who discontinue treatment due to unacceptable toxicity to oblimersen may continue to receive standard therapy comprising CHOP-R. NOTE: *Patients treated at the British Columbia Cancer Agency receive cyclophosphamide, doxorubicin, vincristine, and rituximab on days 1 and 2 and prednisone as above. Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 10 patients are treated at that dose level. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 19-28 patients will be accrued for this study within 5-10 months.


DISEASE CHARACTERISTICS: - Histologically confirmed* CD20+ diffuse large B-cell lymphoma, including any of the following stages: - Extensive stage II (not radio-encompassable within a single involved field or not a candidate for brief chemotherapy and radiotherapy) - Bulky stage II (any single mass greater than 10 cm) - Stage III - Stage IV NOTE: *Confirmed by tissue biopsy - Previously untreated disease - Measurable disease - At least 2 cm by imaging studies - Circulating lymphoma cells no greater than 5,000/mm^3 - No history of other lymphoproliferative disorder - No history of indolent lymphoma - No T-cell lymphoma - No CNS involvement - No post-transplantation lymphoproliferative disorder PATIENT CHARACTERISTICS: Age - 19 and over Performance status - ECOG 0-2 Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 (unless due to bone marrow involvement with lymphoma) - Platelet count at least 100,000/mm^3 (unless due to splenomegaly or bone marrow involvement with lymphoma) Hepatic - Bilirubin no greater than 3 mg/dL (unless due to lymphoma) - No known hepatitis B virus Renal - Creatinine no greater than 2 mg/dL (unless due to lymphoma) Cardiovascular - No cardiac contraindication to doxorubicin therapy (e.g., abnormal contractility on echocardiography) - History of cardiac disease allowed provided ejection fraction is normal Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Adequate venous access - HIV negative - No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer, localized basal cell or squamous cell skin cancer, or curatively treated carcinoma in situ of the cervix - No neurological contraindication to vincristine (e.g., peripheral neuropathy) - No active systemic infection - No medical condition that would compromise study treatment, add toxicity, or impair assessment PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior systemic chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy - Prior radiotherapy for localized basal cell or squamous cell skin cancer used with curative intent allowed Surgery - Not specified



Primary Contact:

Study Chair
Richard J. Klasa, MD
British Columbia Cancer Agency

Backup Contact:


Location Contact:

Stanford, California 94305
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.